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KIT (4q12) - Courtesy Mariano Rocchi. 
DNA/RNA 
Description 
Spans over 70 kb; 21 exons; size of intron 1: >30 
kb. 
Transcription 
5,23 kb mRNA; alternative splicing of exon 9 gives 
rise to two isoforms, KITA and KIT, that differ by 
the presence or absence of four amino acids. 
Protein 
Description 
976 aa; 145 kDa; type III receptor tyrosine kinase; 
contains an extracellular domains with 5 Ig-like 
loops, a highly hydrophobic transmembrane domain 
(23 aa), and an intracellular domain with tyrosine 
kinase activity split in an ATP-binding region and 
in the phosphotransferase domain by a kinase insert 
(KI). 
Expression 
Hematopoietic stem cells, mast cells, melanocytes, 





SCF/MGF receptor with tyrosine kinase activity; 
binding of ligand (SCF) induces receptor 
dimerization, autophosphorylation and signal 
transduction via molecules containing SH2- 
domains. 
Homology 
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In piebaldism, and in familial gastrointestinal 
stromal tumours (see below). 
Somatic 
In aggressive mastocytosis, mast cell leukemia, 
AML with mast cell involvement, 
myeloproliferative disorders, colon carcinoma and 




Autosomal dominant disorder of pigmentation; loss 
of function abnormalities of the c-KIT gene have 
been demonstrated in 59% of the typical patients. 
Familial gastrointestinal stromal 
tumours and sporadic 
gastrointestinal stromal tumours 
(GISTs) 
Disease 
GISTs are the most common mesenchymal tumors 
in the human digestive tract; they originate from 
KIT-expressing cells (ICCs), and were found to 
have activating c-KIT mutations in the 
juxtamembrane domain. 
Systemic mast cell disease (SMCD) 
Disease 
Mast cell hyperplasia in the bone marrow, liver, 
spleen, lymph nodes, gastrointestinal tract and skin; 
gain of function mutations have been detected in a 
few patients. 
Prognosis 
Depending on the four clinical entities recognized: 
indolent form, form associated with hematologic 
disorder, aggressive SMCD and mast cell leukemia; 
leukemic transformation with mast cell 
involvement is characterized by rapid progression 
of disease with a survival time less than 1 year. 
Oncogenesis 
Clinical features of malignant hematopoietic cell 
growth are influenced by the time, the location of c-
KIT mutative events, and the number of associated 
lesions. 
To be noted 
Note 
Loss of expression of c-KIT appears to be 
associated with progression of some tumors 
(melanoma) and autocrine/paracrine stimulation of 
the c-KIT/SCF system may participate in human 
solid tumors such as lung, breast, testicular and 
gynecological malignancies. 
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